השוואת שיטות
סקרו את השיטות שבחרתם זו לצד זו; שורות שבהן יש הבדל מודגשות.
| מבחן חדירות תאי Caco-2× | פרמקוקינטיקה מבוססת-פיזיולוגיה× | |
|---|---|---|
| תחום | פרמקולוגיה | פרמקולוגיה |
| משפחה | Process / pipeline | Process / pipeline |
| שנת המקור≠ | 1989 | 1997 |
| הוגה השיטה≠ | Ingrid Hidalgo | Ivan Nestorov |
| סוג≠ | absorption screening | predictive modeling |
| מקור מכונן≠ | Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749. DOI ↗ | Nestorov, I. (1997). Sensitivity analysis of pharmacokinetic and pharmacodynamic systems. Journal of Pharmacokinetics and Biopharmaceutics, 25(4), 529-543. link ↗ |
| כינויים≠ | Caco-2 assay, intestinal permeability, ADME screening | PBPK, PBPK modeling |
| קשורות | 3 | 3 |
| תקציר≠ | The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport. | PBPK is a mechanistic modeling framework that uses physiological parameters, tissue properties, and drug-specific attributes to predict drug concentration time profiles in the body. Developed rigorously in the 1990s by researchers including Nestorov, PBPK integrates anatomy, biochemistry, and kinetics to enable rational drug development, bridging in vitro data to clinical outcomes. |
| ScholarGateמערך נתונים ↗ |
|
|